Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 324
- Registration Number
- NCT00431431
Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDiabetes Mellitus, Type 2Coronary Disease
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 93
- Registration Number
- NCT00423488
Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 379
- Registration Number
- NCT00423995
Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 722
- Registration Number
- NCT00424008
The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)
Phase 3
Terminated
- Conditions
- Sinusitis
- Interventions
- Drug: MFNS and antibioticDrug: Matching Placebo nasal spray plus antibiotic
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 237
- Registration Number
- NCT00423176
The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)
Phase 4
Completed
- Conditions
- Coronary DiseaseHypercholesterolemia
- Interventions
- Drug: Ezetimibe/Simvastatin 10/20 mgDrug: simvastatin 40 mg
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 120
- Registration Number
- NCT00423579
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1053
- Registration Number
- NCT00418834
Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Ezetimibe with SimvastatinDrug: Placebo
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 392
- Registration Number
- NCT00413972
Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)
Phase 3
Completed
- Conditions
- Sexual Dysfunction
- Interventions
- Drug: tiboloneDrug: estradiol-norethisterone
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 358
- Registration Number
- NCT00413764
Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: NOMAC-E2Drug: DRSP-EE
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2281
- Registration Number
- NCT00413062
© Copyright 2025. All Rights Reserved by MedPath